Street Poller Media and The Boom of the Street Interview Ad Industry 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Toyota Global Sales Fall as China Demand Slumps 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Add as a preferred source on Google
VANCOUVER, British Columbia, April 13, 2018 -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products is clarifying that the current halt on the stock is management requested pending material news. Management anticipates resumption of trading on or before April 17th, 2018.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
604-409-4409
INVESTOR RELATIONS:
[email protected]
www.isodiol.com
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
